Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

BACKGROUND: Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an effective treatment for NRG1 fusion‐driven tumors. PATIENTS AND METHODS: This report summarizes pertinent details, includ...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Cadranel, Jacques, Liu, Stephen V., Duruisseaux, Michaël, Branden, Eva, Goto, Yasushi, Weinberg, Benjamin A., Heining, Christoph, Schlenk, Richard F., Cheema, Parneet, Jones, Martin R., Drilon, Alexander, Trombetta, Domenico, Muscarella, Lucia Anna, Tolba, Khaled, Gounant, Valerie, Cseh, Agnieszka, Solca, Flavio, Laskin, Janessa J., Renouf, Daniel J.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2020
Fag:
Precision Medicine Clinic: Molecular Tumor Board
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794194/
https://ncbi.nlm.nih.gov/pubmed/32852072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0379
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker